Cannabis Science & Policy Summit - Day 1 - Wetterau
•
1 like•243 views
1. ASAM supports decriminalizing marijuana possession for personal use and treating it as a civil offense linked to contingencies like mandated clinical assessment and treatment. 2. ASAM does not support legalizing marijuana and recommends caution in jurisdictions that have not legalized it yet until more is learned from places that have. 3. The document outlines several recommendations from ASAM for regulating legalized recreational marijuana and expanding access to treatment and prevention services for marijuana use, especially among youth.
Report
Share
Report
Share
Download to read offline
Recommended
Cannabis Science & Policy Summit - Day 1 - Caulkins
This document discusses different aspects of legalizing marijuana, including defining levels of legalization and comparing marijuana legalization to other regulated substances and markets. It also provides statistics on current marijuana use patterns in the US, highlighting that most use is concentrated among relatively heavy users and those with substance abuse problems. The potential public health impacts of legalization are uncertain and will depend on how regulations shape the legal market.
Cannabis Science & Policy Summit - Day 2 - Novak
This document summarizes a study that used latent class analysis to identify patterns of medical cannabis consumption among 50 patients in San Francisco. The analysis identified 4 classes: pure therapy (10%), pure euphoria (10%), mixed motives (55%), and smoked euphoria (25%). Characteristics like gender, medical conditions, and socioeconomic status were associated with class membership. Probability of consumption varied by day of week and payday cycles, with higher use on weekends and paydays. The findings suggest medical cannabis is used more for euphoria than purely medical reasons for most patients.
Cannabis Science & Policy Summit - Day 1 - Hall
This document discusses complications that arise when comparing the risks of alcohol and cannabis. While cannabis appears less harmful than alcohol in some ways, its legal status and patterns of use are confounded by prohibition. Additionally, risks may increase with legalization, such as from more potent products, and cannabis use has been correlated with poorer cognitive and social outcomes from sustained daily use. Finally, there are regulatory and health education challenges to legalizing cannabis in a way that minimizes risks of dependence and impairment while developing credible public health advice.
Cannabis Science & Policy Summit - Day 2 - Reuter
1) Canada is taking a sensible approach to legalizing cannabis by planning in advance, articulating specific goals, developing an evaluation process, and coordinating federal and provincial governments.
2) A report from CAMH advocates for a government monopoly over supply to allow for adjustments to product mix as understanding of harms increases, and argues this approach promotes health equity by reducing arrests of minorities and poor people under prohibition.
3) However, the report is criticized for not adequately recognizing potential benefits of cannabis use or considering whether pleasure should count in policymaking, and relying too much on a health model without considering other social harms.
Cannabis Science & Policy Summit - Day 1 - Seiveright
Jamaica has recently passed legislation decriminalizing possession of small amounts of cannabis and legalizing its medical use. This represents progress toward reforming cannabis laws, which were made stricter under British rule and international treaties, despite cannabis having traditional medical and religious uses in Jamaica. The new law allows possession of up to 2 ounces, cultivation of up to 5 plants per household, and imports/exports for medical or scientific purposes. However, regulations are still pending and challenges remain regarding banking restrictions and reactions from other countries.
Cannabis Science & Policy Summit - Day 2 - Sterling
The document summarizes Maryland's medical cannabis program, including:
1) The program was created in 2013 and is overseen by the Natalie M. LaPrade Medical Cannabis Commission. The statute and regulations govern growing, processing, dispensing and use of medical cannabis.
2) Strict security and safety measures are in place, including background checks, video surveillance, inventory tracking from "seed to sale", and limits on the number of growers and dispensaries.
3) The program is funded entirely through license fees, not taxpayer money. Licenses have been awarded for growing, processing and dispensing medical cannabis.
Cannabis Science & Policy Summit - Day 1 - Williams
The document summarizes state medical marijuana programs in the United States. It finds that there is great variation among state programs, with an average score of 1.96 out of 7 on factors reflecting a medical model. Programs enacted more recently through state legislatures in Northeastern and Midwestern states (medicalized programs) tend to be more highly regulated compared to earlier voter initiative programs in Western states (non-medical programs). Medicalized programs have fewer participants, with an average of 58 enrollments per 100,000 residents compared to over 1,000 in non-medical programs. The presentation concludes with a case study of New York's strictly regulated medical marijuana program.
Rx16 vs nadcp_tues_800_1_walton
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
Recommended
Cannabis Science & Policy Summit - Day 1 - Caulkins
This document discusses different aspects of legalizing marijuana, including defining levels of legalization and comparing marijuana legalization to other regulated substances and markets. It also provides statistics on current marijuana use patterns in the US, highlighting that most use is concentrated among relatively heavy users and those with substance abuse problems. The potential public health impacts of legalization are uncertain and will depend on how regulations shape the legal market.
Cannabis Science & Policy Summit - Day 2 - Novak
This document summarizes a study that used latent class analysis to identify patterns of medical cannabis consumption among 50 patients in San Francisco. The analysis identified 4 classes: pure therapy (10%), pure euphoria (10%), mixed motives (55%), and smoked euphoria (25%). Characteristics like gender, medical conditions, and socioeconomic status were associated with class membership. Probability of consumption varied by day of week and payday cycles, with higher use on weekends and paydays. The findings suggest medical cannabis is used more for euphoria than purely medical reasons for most patients.
Cannabis Science & Policy Summit - Day 1 - Hall
This document discusses complications that arise when comparing the risks of alcohol and cannabis. While cannabis appears less harmful than alcohol in some ways, its legal status and patterns of use are confounded by prohibition. Additionally, risks may increase with legalization, such as from more potent products, and cannabis use has been correlated with poorer cognitive and social outcomes from sustained daily use. Finally, there are regulatory and health education challenges to legalizing cannabis in a way that minimizes risks of dependence and impairment while developing credible public health advice.
Cannabis Science & Policy Summit - Day 2 - Reuter
1) Canada is taking a sensible approach to legalizing cannabis by planning in advance, articulating specific goals, developing an evaluation process, and coordinating federal and provincial governments.
2) A report from CAMH advocates for a government monopoly over supply to allow for adjustments to product mix as understanding of harms increases, and argues this approach promotes health equity by reducing arrests of minorities and poor people under prohibition.
3) However, the report is criticized for not adequately recognizing potential benefits of cannabis use or considering whether pleasure should count in policymaking, and relying too much on a health model without considering other social harms.
Cannabis Science & Policy Summit - Day 1 - Seiveright
Jamaica has recently passed legislation decriminalizing possession of small amounts of cannabis and legalizing its medical use. This represents progress toward reforming cannabis laws, which were made stricter under British rule and international treaties, despite cannabis having traditional medical and religious uses in Jamaica. The new law allows possession of up to 2 ounces, cultivation of up to 5 plants per household, and imports/exports for medical or scientific purposes. However, regulations are still pending and challenges remain regarding banking restrictions and reactions from other countries.
Cannabis Science & Policy Summit - Day 2 - Sterling
The document summarizes Maryland's medical cannabis program, including:
1) The program was created in 2013 and is overseen by the Natalie M. LaPrade Medical Cannabis Commission. The statute and regulations govern growing, processing, dispensing and use of medical cannabis.
2) Strict security and safety measures are in place, including background checks, video surveillance, inventory tracking from "seed to sale", and limits on the number of growers and dispensaries.
3) The program is funded entirely through license fees, not taxpayer money. Licenses have been awarded for growing, processing and dispensing medical cannabis.
Cannabis Science & Policy Summit - Day 1 - Williams
The document summarizes state medical marijuana programs in the United States. It finds that there is great variation among state programs, with an average score of 1.96 out of 7 on factors reflecting a medical model. Programs enacted more recently through state legislatures in Northeastern and Midwestern states (medicalized programs) tend to be more highly regulated compared to earlier voter initiative programs in Western states (non-medical programs). Medicalized programs have fewer participants, with an average of 58 enrollments per 100,000 residents compared to over 1,000 in non-medical programs. The presentation concludes with a case study of New York's strictly regulated medical marijuana program.
Rx16 vs nadcp_tues_800_1_walton
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
Rx16 adv wed_1230_1_thau_2gorman
This document provides a summary of a presentation on the risks of medical marijuana and marijuana legalization. It begins with disclosures from the presenters and outlines six learning objectives. It then discusses concerns that marijuana is addictive, especially for those who start using it early, and impacts adolescent brain development. The document notes the lack of evidence that marijuana is effective for the conditions it is claimed to treat. It also discusses the risks of increased diversion of marijuana to youth and greater social acceptance of marijuana use negatively impacting public health. The document concludes with messages on how to discuss these issues with the public.
Rx16 len wed_330_1_ferdinand_2price
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
Rx16 pharma tues_330_1_painter_2lev_3green
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
Alcohol drugs_2-27-2013_412652_7
Teen drug and alcohol abuse can lead to serious health risks such as liver damage, psychotic behavior, and harm to vital organs. Binge drinking teens are much more likely to abuse other drugs - they are 4 times more likely to abuse painkillers and 15 times more likely to abuse prescription drugs without a doctor's prescription compared to non-drinking teens. Parents, schools, and communities can work together to implement prevention programs and policies to reduce teen substance abuse through education, monitoring, and limiting availability.
Rx16 claad tue-vision_final
Addiction Is A Disease, Not A Choice, And Should Be Treated As Such - updated to correct error 4-11-16
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
This document summarizes presentations from public health officials in North Carolina and Northern Kentucky on community responses to the heroin epidemic. Key points include:
- Officials from North Carolina and Northern Kentucky outlined programs and partnerships implemented in their regions to address rising rates of opioid and heroin abuse, including treatment programs, harm reduction strategies, legislation, and education initiatives.
- Data presented showed increasing rates of overdose deaths, neonatal abstinence syndrome, and infectious diseases associated with intravenous drug use such as hepatitis C in Northern Kentucky.
- Community leaders and advocates in Northern Kentucky have worked to raise awareness, pass legislation to expand access to treatment, and establish prevention and support networks to address the heroin epidemic impacting the region.
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
This document summarizes a presentation on state and community-level programs for preventing prescription drug misuse and expanding treatment options like medication-assisted treatment. Speakers from Georgia and Iowa discussed their strategies for engaging stakeholders, implementing prevention initiatives in targeted communities, leveraging funding sources, and addressing challenges in data and addressing disparities. Iowa described their efforts to expand access to medication-assisted treatment for opioid use disorders through a new grant, including challenges implementing changes quickly.
Marijuana powerpoint
A powerpoint about the issue revolving around marijuana use and legalization. More specifically about how it effects the economy and people when you legalize it's recreational use, but classify it as an illicit drug in drug tests.
Rx16 federal wed_1230_1_kelly_2bohn-killorin
1) The National HIDTA Program provides assistance to law enforcement agencies in critical drug trafficking regions through 28 regional HIDTA programs. It facilitates cooperation among federal, state, local, and tribal law enforcement.
2) Each HIDTA program has an executive board that identifies threats, develops strategies, and requests funding for initiatives. It brings together over 7,400 federal agents, 15,700 state and local officers, and 500 agencies across the country.
3) In response to the opioid epidemic, HIDTA employs law enforcement targeting of heroin and fentanyl trafficking, public health prevention efforts, and training on investigating heroin organizations. It has committed additional funds to enhance intelligence sharing and public health partnerships.
Rx16 len tues_200_1_beshear_2ohr-menendez
This document summarizes a presentation on state and federal responses to the opioid epidemic. It discusses innovations from the Kentucky Attorney General including legislative measures targeting pill mills and heroin, programs to expand treatment and recovery, and education initiatives. It also describes the federal response through the Organized Crime Drug Enforcement Task Force (OCDETF), including their national heroin initiative targeting criminal organizations trafficking illegal opioids and heroin, and partnerships with other agencies to address public health and public safety aspects of the epidemic. The presentation outlines strategies at both state and federal levels aimed at improving access to treatment while also enforcing penalties on dealers through investigation and prosecution efforts.
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
Rx16 advocacy wed_200_1_mendell_2manlove
This document provides information about an advocacy track presentation on advocating for change related to addiction issues. The presentation features Gary Mendell, founder and CEO of Shatterproof, and Kim Manlove from the Indiana Addictions Issues Coalition. They will discuss strategies for influencing legislation and how people in recovery can become advocates. The learning objectives focus on advocating for state laws on PDMP usage, explaining strategies to influence legislation, describing how people in recovery can advocate, and providing counsel as part of a treatment team. The presentation then provides details on Shatterproof's story, the overdose epidemic, solutions for different populations, and legislative accomplishments in various states related to expanding access to naloxone and mandating PDMP usage.
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
This document discusses patient review and restriction programs (PRRs) as tools to help curb prescription drug abuse and coordinate patient care. It describes state Medicaid PRR programs and recent efforts to expand PRR programs to Medicare. It also describes the role of PRR programs in the CDC's Prescription Drug Overdose Prevention for States grant program, the Office of National Drug Control Policy's national strategy, and the federal budget.
Rx16 clinical tues_200_1_samuels_2waller_3_lynch_4earle
The document discusses strategies for engaging opioid overdose patients in addiction treatment after receiving naloxone/an overdose reversal. It describes:
1) The Lifespan Opioid Overdose Prevention Program in Rhode Island which aims to reduce overdose deaths by increasing access to naloxone, expanding overdose education in EDs, and increasing referral to treatment. The program provides take-home naloxone, peer recovery coaching, and refers patients to treatment.
2) The Camden County Addiction Awareness Task Force's "Operation SAL" program which aims to engage overdose patients in treatment after being revived by first responders. It connects patients to resources like food/clothing banks and
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
This document summarizes a presentation on a study examining how prescriber registration and use of a prescription drug monitoring program (PDMP) in Oregon impacted opioid prescribing patterns and patient outcomes. The study found that statewide opioid prescribing generally decreased over time, but prescribers who registered for the PDMP prescribed more after registering, especially those who used the PDMP most frequently. In contrast, prescribers who did not register prescribed less. Patients whose providers were all registered had lower overdose rates than those with some registered and some non-registered providers. The conclusions were that PDMPs may need refinements like mandatory use to optimize their impact on prescribing and outcomes.
Rx16 pharma wed_1115_1_ryle_2menkhaus_3mcginley
This document discusses a presentation on whether pharmacists should fill opioid prescriptions or not. It includes the presenters, learning objectives, and disclosures. It then summarizes Karen Ryle's presentation on red flags pharmacists should watch out for when dispensing controlled substances like opioids. These include things like "cocktailed" prescriptions, no individualized dosing, early refills, out-of-area doctors and patients, and mostly cash prescriptions. It also discusses integrating prescription drug monitoring program data into pharmacy workflows to more easily check for signs of abuse or diversion.
Sub m mw actual
This document provides information about substance misuse, including harmful effects on individuals and society. It identifies sources of help for substance misuse and sources of information about drug use rates. The document also discusses government policy approaches to substance misuse, which include legal controls, treatment options, and preventative education. It provides statistics about illicit drug use in England and Wales from the Crime Survey and poses discussion questions.
Addiction Medicine: Closing the Gap between Science and Practice
These slides accompany CASAColumbia's report, Addiction Medicine: Closing the Gap between Science and Practice, published in June 2012, which found that, despite the prevalence of addiction, the enormity of its consequences, the availability of effective solutions and the evidence that addiction is a disease, both screening and early intervention for risky substance use are rare, and only about 1 in 10 people with addiction involving alcohol or drugs other than nicotine receive any form of treatment.
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
This document summarizes a presentation on best practices for treating opioid addiction in the criminal justice population. It outlines the challenges of treatment in this population and identifies best practices for using medication-assisted treatment (MAT) and behavioral therapy. The presentation reviews key points from the ASAM National Practice Guideline, including that MAT is the standard of care for opioid use disorder and should be continued, initiated, or made available for inmates. Discontinuing treatment can be dangerous and contradicts evidence-based practices. The implications discussed are that the guideline supports higher quality care for inmates and a rehabilitative approach, while also helping to address the opioid epidemic.
Cannabis Science & Policy Summit - Day 1 - Kagan
This document discusses options for regulating recreational marijuana in California if legalized. It recommends taking a relatively tight initial regulatory approach to create a single market, building in the ability to change regulations over time based on data, and requiring extensive data collection. Key regulatory areas to focus on include cultivation and production licensing, restricting sales to adults, establishing taxes, preventing impaired driving and abuse, and designating an oversight agency. An effective regulatory system would manage the entire supply chain, limit youth access, raise revenue, and monitor public health and safety impacts ongoing.
Cannabis Science & Policy Summit - Day 1 - Courtwright
The document discusses regulating cannabis as a "temptation good" by learning from other vices like alcohol and proposes a "Goth-Pot" system where cannabis would be produced and sold by a public monopoly trust with limited advertising, retail locations, and product potency to prevent abuse and unwanted habits, similar to Sweden's historical Gothenburg System for regulating alcohol. It also includes poll data showing most Americans see tobacco as more harmful than alcohol, sugar, or marijuana.
More Related Content
What's hot
Rx16 adv wed_1230_1_thau_2gorman
This document provides a summary of a presentation on the risks of medical marijuana and marijuana legalization. It begins with disclosures from the presenters and outlines six learning objectives. It then discusses concerns that marijuana is addictive, especially for those who start using it early, and impacts adolescent brain development. The document notes the lack of evidence that marijuana is effective for the conditions it is claimed to treat. It also discusses the risks of increased diversion of marijuana to youth and greater social acceptance of marijuana use negatively impacting public health. The document concludes with messages on how to discuss these issues with the public.
Rx16 len wed_330_1_ferdinand_2price
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
Rx16 pharma tues_330_1_painter_2lev_3green
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
Alcohol drugs_2-27-2013_412652_7
Teen drug and alcohol abuse can lead to serious health risks such as liver damage, psychotic behavior, and harm to vital organs. Binge drinking teens are much more likely to abuse other drugs - they are 4 times more likely to abuse painkillers and 15 times more likely to abuse prescription drugs without a doctor's prescription compared to non-drinking teens. Parents, schools, and communities can work together to implement prevention programs and policies to reduce teen substance abuse through education, monitoring, and limiting availability.
Rx16 claad tue-vision_final
Addiction Is A Disease, Not A Choice, And Should Be Treated As Such - updated to correct error 4-11-16
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
This document summarizes presentations from public health officials in North Carolina and Northern Kentucky on community responses to the heroin epidemic. Key points include:
- Officials from North Carolina and Northern Kentucky outlined programs and partnerships implemented in their regions to address rising rates of opioid and heroin abuse, including treatment programs, harm reduction strategies, legislation, and education initiatives.
- Data presented showed increasing rates of overdose deaths, neonatal abstinence syndrome, and infectious diseases associated with intravenous drug use such as hepatitis C in Northern Kentucky.
- Community leaders and advocates in Northern Kentucky have worked to raise awareness, pass legislation to expand access to treatment, and establish prevention and support networks to address the heroin epidemic impacting the region.
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
This document summarizes a presentation on state and community-level programs for preventing prescription drug misuse and expanding treatment options like medication-assisted treatment. Speakers from Georgia and Iowa discussed their strategies for engaging stakeholders, implementing prevention initiatives in targeted communities, leveraging funding sources, and addressing challenges in data and addressing disparities. Iowa described their efforts to expand access to medication-assisted treatment for opioid use disorders through a new grant, including challenges implementing changes quickly.
Marijuana powerpoint
A powerpoint about the issue revolving around marijuana use and legalization. More specifically about how it effects the economy and people when you legalize it's recreational use, but classify it as an illicit drug in drug tests.
Rx16 federal wed_1230_1_kelly_2bohn-killorin
1) The National HIDTA Program provides assistance to law enforcement agencies in critical drug trafficking regions through 28 regional HIDTA programs. It facilitates cooperation among federal, state, local, and tribal law enforcement.
2) Each HIDTA program has an executive board that identifies threats, develops strategies, and requests funding for initiatives. It brings together over 7,400 federal agents, 15,700 state and local officers, and 500 agencies across the country.
3) In response to the opioid epidemic, HIDTA employs law enforcement targeting of heroin and fentanyl trafficking, public health prevention efforts, and training on investigating heroin organizations. It has committed additional funds to enhance intelligence sharing and public health partnerships.
Rx16 len tues_200_1_beshear_2ohr-menendez
This document summarizes a presentation on state and federal responses to the opioid epidemic. It discusses innovations from the Kentucky Attorney General including legislative measures targeting pill mills and heroin, programs to expand treatment and recovery, and education initiatives. It also describes the federal response through the Organized Crime Drug Enforcement Task Force (OCDETF), including their national heroin initiative targeting criminal organizations trafficking illegal opioids and heroin, and partnerships with other agencies to address public health and public safety aspects of the epidemic. The presentation outlines strategies at both state and federal levels aimed at improving access to treatment while also enforcing penalties on dealers through investigation and prosecution efforts.
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
Rx16 advocacy wed_200_1_mendell_2manlove
This document provides information about an advocacy track presentation on advocating for change related to addiction issues. The presentation features Gary Mendell, founder and CEO of Shatterproof, and Kim Manlove from the Indiana Addictions Issues Coalition. They will discuss strategies for influencing legislation and how people in recovery can become advocates. The learning objectives focus on advocating for state laws on PDMP usage, explaining strategies to influence legislation, describing how people in recovery can advocate, and providing counsel as part of a treatment team. The presentation then provides details on Shatterproof's story, the overdose epidemic, solutions for different populations, and legislative accomplishments in various states related to expanding access to naloxone and mandating PDMP usage.
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
This document discusses patient review and restriction programs (PRRs) as tools to help curb prescription drug abuse and coordinate patient care. It describes state Medicaid PRR programs and recent efforts to expand PRR programs to Medicare. It also describes the role of PRR programs in the CDC's Prescription Drug Overdose Prevention for States grant program, the Office of National Drug Control Policy's national strategy, and the federal budget.
Rx16 clinical tues_200_1_samuels_2waller_3_lynch_4earle
The document discusses strategies for engaging opioid overdose patients in addiction treatment after receiving naloxone/an overdose reversal. It describes:
1) The Lifespan Opioid Overdose Prevention Program in Rhode Island which aims to reduce overdose deaths by increasing access to naloxone, expanding overdose education in EDs, and increasing referral to treatment. The program provides take-home naloxone, peer recovery coaching, and refers patients to treatment.
2) The Camden County Addiction Awareness Task Force's "Operation SAL" program which aims to engage overdose patients in treatment after being revived by first responders. It connects patients to resources like food/clothing banks and
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
This document summarizes a presentation on a study examining how prescriber registration and use of a prescription drug monitoring program (PDMP) in Oregon impacted opioid prescribing patterns and patient outcomes. The study found that statewide opioid prescribing generally decreased over time, but prescribers who registered for the PDMP prescribed more after registering, especially those who used the PDMP most frequently. In contrast, prescribers who did not register prescribed less. Patients whose providers were all registered had lower overdose rates than those with some registered and some non-registered providers. The conclusions were that PDMPs may need refinements like mandatory use to optimize their impact on prescribing and outcomes.
Rx16 pharma wed_1115_1_ryle_2menkhaus_3mcginley
This document discusses a presentation on whether pharmacists should fill opioid prescriptions or not. It includes the presenters, learning objectives, and disclosures. It then summarizes Karen Ryle's presentation on red flags pharmacists should watch out for when dispensing controlled substances like opioids. These include things like "cocktailed" prescriptions, no individualized dosing, early refills, out-of-area doctors and patients, and mostly cash prescriptions. It also discusses integrating prescription drug monitoring program data into pharmacy workflows to more easily check for signs of abuse or diversion.
Sub m mw actual
This document provides information about substance misuse, including harmful effects on individuals and society. It identifies sources of help for substance misuse and sources of information about drug use rates. The document also discusses government policy approaches to substance misuse, which include legal controls, treatment options, and preventative education. It provides statistics about illicit drug use in England and Wales from the Crime Survey and poses discussion questions.
Addiction Medicine: Closing the Gap between Science and Practice
These slides accompany CASAColumbia's report, Addiction Medicine: Closing the Gap between Science and Practice, published in June 2012, which found that, despite the prevalence of addiction, the enormity of its consequences, the availability of effective solutions and the evidence that addiction is a disease, both screening and early intervention for risky substance use are rare, and only about 1 in 10 people with addiction involving alcohol or drugs other than nicotine receive any form of treatment.
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
This document summarizes a presentation on best practices for treating opioid addiction in the criminal justice population. It outlines the challenges of treatment in this population and identifies best practices for using medication-assisted treatment (MAT) and behavioral therapy. The presentation reviews key points from the ASAM National Practice Guideline, including that MAT is the standard of care for opioid use disorder and should be continued, initiated, or made available for inmates. Discontinuing treatment can be dangerous and contradicts evidence-based practices. The implications discussed are that the guideline supports higher quality care for inmates and a rehabilitative approach, while also helping to address the opioid epidemic.
What's hot (20)
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 heroin tues_330_1_moser_2proescholdbell-sachdeva
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 clinical tues_200_1_samuels_2waller_3_lynch_4earle
Rx16 clinical tues_200_1_samuels_2waller_3_lynch_4earle
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Addiction Medicine: Closing the Gap between Science and Practice
Addiction Medicine: Closing the Gap between Science and Practice
Viewers also liked
Cannabis Science & Policy Summit - Day 1 - Kagan
This document discusses options for regulating recreational marijuana in California if legalized. It recommends taking a relatively tight initial regulatory approach to create a single market, building in the ability to change regulations over time based on data, and requiring extensive data collection. Key regulatory areas to focus on include cultivation and production licensing, restricting sales to adults, establishing taxes, preventing impaired driving and abuse, and designating an oversight agency. An effective regulatory system would manage the entire supply chain, limit youth access, raise revenue, and monitor public health and safety impacts ongoing.
Cannabis Science & Policy Summit - Day 1 - Courtwright
The document discusses regulating cannabis as a "temptation good" by learning from other vices like alcohol and proposes a "Goth-Pot" system where cannabis would be produced and sold by a public monopoly trust with limited advertising, retail locations, and product potency to prevent abuse and unwanted habits, similar to Sweden's historical Gothenburg System for regulating alcohol. It also includes poll data showing most Americans see tobacco as more harmful than alcohol, sugar, or marijuana.
Cannabis Science & Policy Summit - Day 1 - Peyraube
Uruguay has reformed its drug policy based on a framework of security, public health, and human rights. It prioritizes human rights conventions and national sovereignty over international drug conventions. Uruguay regulates cannabis to reduce the negative impacts of drugs and incarceration for possession. The regulation creates a domestic cannabis industry and allows medical use and research. Adults can access cannabis through self-cultivation, cannabis clubs, or purchasing up to 40 grams per month from pharmacies. Production is licensed and regulated by the government.
Cannabis Science & Policy Summit - Day 1 - MacCoun
This document summarizes key points from Jon's talk on cannabis legalization. It notes that national legalization following an alcohol model is likely. Long-run cannabis consumption may double. Prices and quantity consumed matter more than the number of consumers. There are many policy levers but it is unclear if they are being used effectively to learn what works. National legalization is not guaranteed and effects in states like Colorado are still uncertain due to many complicating factors. The fundamental tradeoff is that legalization may reduce average harm per dose while increasing total doses consumed, with the net public health effect unknown.
Cannabis Science & Policy Summit - Day 1 - Mead
This document discusses GW Pharmaceuticals' investigation of Cannabidiol (CBD) as a potential therapeutic product. GW Pharmaceuticals is developing a purified CBD product called Epidiolex to treat rare and severe forms of childhood epilepsy. Clinical trials showed Epidiolex significantly reduced seizures in patients with Dravet Syndrome. If approved by the FDA, Epidiolex would be the first prescription drug in the United States containing a purified drug substance derived from cannabis. The FDA approval process ensures patient safety and requires rigorous clinical trials, but takes years and is expensive.
Cannabis Science & Policy Summit - Day 1 - Cruz
This document summarizes research on cannabis legalization in Uruguay. It discusses four areas of focus: public opinion analysis, impact on frequent consumers, cannabis clubs, and retail distribution. The presentation specifically discusses national surveys showing most Uruguayans initially disagreed with legalization but viewed medical cannabis and state intervention favorably, though many felt use had increased. However, data on use was inconsistent. Implementation of the cannabis law faces challenges of general disapproval, concerns over pharmacy distribution, and needs better communication and prevention strategies.
Cannabis Science & Policy Summit - Day 1 - Rolles
The document outlines 10 steps for designing legal access to cannabis: 1) agree on policy aims and principles; 2) establish a methodology to evaluate policy impacts; 3) establish an independent commission of experts to develop policy details; 4) identify and mitigate key risks learned from regulating alcohol and tobacco; 5) ensure enforcement structures and capacity for any new regulatory framework. The steps also include controlling commercial incentives to increase consumption; initially meeting existing demand through legal supply roughly matching illegal supply; avoiding diversifying cannabis products and prohibiting advertising as much as possible; and balancing market access and appeal.
Cannabis Science & Policy Summit - Day 1 - Jelsma
This document discusses cannabis regulation and the UN drug control treaties. It notes that the 1961 Single Convention placed cannabis in Schedule I and IV, requiring abolition of traditional and medical uses. However, some countries were allowed transitional reservations for traditional use. The document questions whether the WHO ever properly reviewed cannabis or recommended its scheduling. It discusses options for reforming the UN drug treaties to allow more flexibility for countries to design their own cannabis policies.
Cannabis Science & Policy Summit - Day 2 - Jacobson
This document discusses the future of medical cannabis. It outlines a spectrum of cannabis use from medical to therapeutic/wellness to recreational. While some conditions like cancer pain, nausea, and epilepsy have seen medical cannabis legalized, mainstream medicine does not recognize it as a legitimate treatment due to a lack of chemical definition and clinical research. More research is needed to establish safe and effective dosing as well as drug interactions before medical cannabis can be fully accepted. The current system also fails patients in terms of accessibility, insurance coverage, and appropriate medical supervision.
Cannabis Science & Policy Summit - Day 1 - Sabet
This document discusses alternatives to legalizing marijuana that were presented in a RAND report on Vermont. It notes that most of the options presented in the RAND report were still versions of legalization, and that there are other models that do not involve legalizing marijuana. These include civil citation programs that require drug assessment, community service, and interventions for first-time offenders, diversion programs requiring drug education or treatment, and decriminalization laws requiring drug education or treatment following an offense. The document provides examples of such programs in Florida, New Jersey, Maryland, and Maryland's decriminalization law.
Cannabis Science & Policy Summit - Day 1 - Midgette
This document summarizes a report on marijuana legalization in Vermont. It finds that marijuana use is more prevalent in Vermont than the rest of the US. Currently, Vermont spends $800,000-$1.1 million annually prohibiting marijuana. The report discusses 12 policy alternatives to the status quo and models potential tax revenue from legalization, finding it could be in the tens of millions annually from Vermont users alone. However, regulation costs and uncertainty around impacts on substance use make projections difficult.
Cannabis Science & Policy Summit - Day 2 - de Kort
The document summarizes the origins and development of Dutch cannabis policy from the 1970s to the present. Key events included the recommendations of committees in the late 1960s and early 1970s to decriminalize cannabis, the introduction of heroin in 1972 which led to stricter drug laws, and the rise of coffee shops in the 1970s-1980s which established a system of toleration for soft drugs like cannabis. The coffee shop system developed pragmatically rather than through a formal policy and expectations of legalization were not met. Over time coffee shops faced some regulation to address issues like advertising, hard drugs, nuisances, and minors.
Cannabis Science & Policy Summit - Day 2 - Blickman
The document summarizes the debate around regulating the cannabis supply system in the Netherlands. It outlines that mayors, judges, and public opinion favor regulation over the current policy of tolerance. The mayors revolt argues that tolerance is bankrupt and increases crime, while judges are increasingly uneasy about contradictions in current policy. The document proposes regulating cultivation and supply to reduce crime and better protect public health.
Cannabis Science & Policy Summit - Day 2 - Hope
The document discusses issues related to cannabis policy in Mexico. It provides statistics on homicides, drug cases, eradication and seizures of marijuana from 2005-2015. It shows that 50% of homicides with firearms from 2007-2014 occurred in regions known for marijuana production. The document also shows data on the percentage of inmates in state penitentiaries that were incarcerated for drug retail sales (5%), crimes against health (7%) and other crimes (88%). It acknowledges that precisely estimating the effects of changing drug policy is impossible and that displacement effects are unknown. It concludes by thanking the audience and providing contact information for Alejandro Hope who presented the information.
Cannabis Science & Policy Summit - Day 2 - Flaster
The document summarizes a panel discussion on adulterants in cannabis regulation and testing, with panelists from various cannabis industry organizations. The panel discusses issues around growing practices, ensuring quality and consistency of cannabis products, and the importance of testing for contaminants and validating test methods to verify constituents and ensure consumer safety. Proper growing, accountability through testing, and transparency were emphasized as important to building trust in the cannabis industry.
Cannabis Science & Policy Summit - Day 2 - MacCoun
This document summarizes research on the Dutch approach to cannabis policy, known as "de facto legalization". Key points include:
- During the first decade after policy change in 1976, cannabis use prevalence did not increase, but sharply rose in the second decade due to commercialization of coffeeshops.
- The Dutch system maintains high cannabis prices through prohibition on growers/traffickers while allowing sale to users, unlike potential US legalization with aggressive marketing and minimal price controls.
- Experts note the Dutch policy was a product of addressing the heroin threat in the 1970s but the policy window has since closed, with unintended consequences like street dealing and production shifting elsewhere.
Cannabis Science & Policy Summit - Day 1 - Fortin
1) The document analyzes cannabis policy and markets in Colorado following legalization of recreational cannabis.
2) It finds evidence that the recreational market is cannibalizing the medical market, especially in tourist counties, but is also expanding overall demand.
3) A dual pricing scheme, with lower prices for medical patients and higher prices for recreational users, has successfully achieved price discrimination and appears optimal for balancing economic and social outcomes.
Cannabis Science & Policy Summit - Day 2 - Trautmann
The national cannabis policy in the Netherlands has swung like a pendulum since the 1990s, moving between more liberal and restrictive approaches. Originally, a more liberal policy developed in response to social changes and protests in the 1960s, allowing for regulated cannabis sales. However, international criticism and issues like drug tourism led to a more restrictive approach focused on supply reduction and public order from the 2000s onward. Stricter measures unintentionally increased street dealing and organized crime involvement. More recently, support has increased for a less restrictive approach, including some cities exploring regulated cannabis production. Current national policy still prohibits production but condones retail sales through "coffeeshops" under local regulations.
Cannabis Science & Police Summit - Day 1 - Zinsmeister
The document discusses public opinion and the UN drug conventions regarding drug policy reforms. It summarizes that legalization is still a minority position at the UN as the majority of member states still favor prohibitionist approaches. Several polls and surveys cited show that public opinion in Europe and Latin America also generally opposes marijuana legalization and favors maintaining prohibition. When asked about decriminalization, reaction is still mixed. The Latin American public sees drugs as both a security and public health issue.
Cannabis Science & Policy Summit - Day 1 - Miller
This document analyzes the legal marijuana market in Washington state using traceability data from the state's seed-to-sale tracking system. Three key findings are: (1) Prices fell substantially over time due to increased supply and competition among producers and processors; (2) While product characteristics changed dramatically, retail quantities were not significantly affected by a tax change, suggesting demand is inelastic; (3) Entry into the market was high initially but has slowed, and supply has increased substantially.
Viewers also liked (20)
Cannabis Science & Policy Summit - Day 1 - Courtwright
Cannabis Science & Policy Summit - Day 1 - Courtwright
Cannabis Science & Policy Summit - Day 1 - Peyraube
Cannabis Science & Policy Summit - Day 1 - Peyraube
Cannabis Science & Policy Summit - Day 1 - MacCoun
Cannabis Science & Policy Summit - Day 1 - MacCoun
Cannabis Science & Policy Summit - Day 2 - Jacobson
Cannabis Science & Policy Summit - Day 2 - Jacobson
Cannabis Science & Policy Summit - Day 1 - Midgette
Cannabis Science & Policy Summit - Day 1 - Midgette
Cannabis Science & Policy Summit - Day 2 - de Kort
Cannabis Science & Policy Summit - Day 2 - de Kort
Cannabis Science & Policy Summit - Day 2 - Blickman
Cannabis Science & Policy Summit - Day 2 - Blickman
Cannabis Science & Policy Summit - Day 2 - Flaster
Cannabis Science & Policy Summit - Day 2 - Flaster
Cannabis Science & Policy Summit - Day 2 - MacCoun
Cannabis Science & Policy Summit - Day 2 - MacCoun
Cannabis Science & Policy Summit - Day 2 - Trautmann
Cannabis Science & Policy Summit - Day 2 - Trautmann
Cannabis Science & Police Summit - Day 1 - Zinsmeister
Cannabis Science & Police Summit - Day 1 - Zinsmeister
Similar to Cannabis Science & Policy Summit - Day 1 - Wetterau
The Brief Wondrous Life of Oscar Wao.docx
This document discusses treatment options for alcohol use disorders. It notes that while treatment options have expanded beyond 12-step programs like Alcoholics Anonymous, most people with alcohol use disorders remain untreated. It summarizes recent research exploring improved diagnosis, medications, behavioral therapies, and ways to broaden treatment access, such as through primary care settings and emerging technologies like online therapy programs.
EVERFI Webinar: Addressing Prescription Drug Abuse on Campus
This document discusses addressing prescription drug abuse on college campuses. It begins by outlining the scope of the problem, noting that while the US makes up 5% of the world's population, it consumes 75% of the world's prescription drugs. Contributing factors to misuse include easy access to medications, misperceptions about safety, and direct-to-consumer drug advertising. The document then defines misuse and outlines the most commonly abused drug types - opioids, stimulants, and depressants. It presents data on misuse rates among college students and 18-25 year olds. Finally, it discusses prevention strategies including information dissemination, skill building, problem identification and referral services, environmental approaches, and campus-
Drug abuse and Illicit trafficking of drugs
The document discusses World Drug Day which is observed annually on June 26th to raise awareness of the global drug problem. It notes that better knowledge is needed to address the drug issue and foster international cooperation. It then provides information on common reasons for teen drug use, latest drug trends including increasing opioid and stimulant abuse, and the impacts of COVID-19 on drug production, trafficking and use. Finally, it outlines the responsibilities of pharmacists in preventing substance abuse through education, monitoring programs, and discouraging overprescribing.
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Currently our country is experiencing a national health crisis of opiate use and opiate related overdoses, with the corona virus causing these problems to only get worse. In 2019 the number of drug overdoses in the United States rose by 4.6% , for a total of 70,980, with 50,042 involving opioids (American Hospital Association, 2020)
It is estimated around 130 people die each day due to overdose and since 2010 a total of 400,000 deaths have occurred (DrugAbuse.Gov)
Following national trends New Mexico has seen an increase in reported overdoses since the early 2000s and in 2018 63.0% of drug overdose deaths involved opioids with a total of more than 338 fatalities.(DrugAbuse.Gov)
Transmission of bloodborne diseases such as HIV and Hepatitis C is also an issue among the population who use intravenously.
Introduction to Quality use of medicine.pptx
The document discusses Quality Use of Medicines (QUM) in Australia. It defines QUM as selecting management options wisely, choosing suitable medicines if needed and using medicines safely and effectively. The key principles of QUM are the primacy of consumers, partnership, consultative and collaborative activities, supporting existing activity, and systems-based approaches. Key partners in QUM include consumers, healthcare providers, educators, facilities, industries, media, funders and governments. The building blocks that support QUM are policy development, coordination, information provision, education and training, services, and research. Evaluation of QUM occurs at the community, institutional and national levels.
Know Your Drugs
This document discusses the importance of patient-centered care and informed decision making when taking prescription drugs. It notes that adverse drug reactions are a leading cause of death and disability worldwide. It emphasizes that patients should question their doctors about prescribed drugs, including potential side effects, interactions, and non-drug treatment alternatives. The document encourages patients to research their medications and report any adverse reactions to help improve pharmacare outcomes and ensure treatments are safe and effective. Overall, it promotes empowering patients to make informed choices about prescription drug use through questioning, researching, sharing knowledge with others, and reporting reactions.
No to drug abuse
This document discusses common reasons teens use drugs like alcohol, including boredom, peer pressure, and desire to alter mood. It describes potential effects of drug and alcohol use like disruption of learning and increased mental health risks. The stages of drug use are outlined from non-use to dependency. The responsibilities of pharmacists in prevention, education, and working with authorities to address substance abuse are also summarized.
PREVENTION OF SUBSTANCE USE AND ABUSE.pptx
The document discusses substance use, abuse, and addiction. It defines key terms like drugs, drug abuse, dependence, misuse, tolerance, and addiction. It describes commonly abused drugs like shabu, marijuana, inhalants, alcohol, heroin, cocaine, marijuana, and methamphetamine. It discusses signs of substance abuse problems and risk/protective factors for drug use. It provides information on the drug situation in the Philippines, including current/lifetime drug use rates and perceptions. The government's anti-drug campaign is also summarized.
Self medication
Self-medication is a growing global concern that can contribute to antimicrobial resistance. While it provides benefits like convenience and cost savings, it also poses risks if not done properly, such as incorrect diagnosis, inappropriate treatment, and adverse drug reactions. Health professionals and pharmacists can help prevent these risks through education, guidance on proper use, and encouraging medical consultation when needed.
RUD and COMPLIANCE
The document discusses rational medication use and patient compliance. It defines rational use as prescribing the appropriate drug, dose, duration and cost to meet a patient's clinical needs. Irrational use can lead to ineffective treatment, prolonged illness and increased costs. The document outlines factors influencing rational use and strategies to improve it, including educational, managerial, economic and regulatory approaches. It also defines adherence versus compliance, discusses causes and measurements of non-compliance, and factors affecting a patient's ability to comply with medication instructions.
Tue vs samhsa - harding
Tuesday Vision Session: Substance Abuse and Mental Health Services Administration (SAMHSA): Examining Prescription Drug Misuse and Abuse from Federal and National Perspectives
Ethics in clinical research
This document discusses ethics in clinical research and medical research. It covers key topics like the principles of ethics, objectives of medical research ethics, functions of medical research, moral problems in clinical research, and ethics requirements. The three main ethical principles are described as justice, respect for persons, and beneficence/non-maleficence. Informed consent, minimizing risks and maximizing benefits, non-exploitation of subjects, and balancing research with patient care are some of the important aspects covered.
Rational drug use
The document discusses rational use of medicines and the role of pharmacists in promoting rational use. It defines rational use of medicines according to WHO as ensuring patients receive appropriate medicines based on their clinical needs at the lowest cost. Pharmacists can promote rational use by properly managing drug stocks, dispensing medications correctly with patient education, and participating in pharmacovigilance programs. The document also outlines several other strategies to improve rational use, including developing treatment guidelines, regulating drug promotion, and educating both healthcare providers and the public.
Rational Drug use - Group 5 presentation 2.0 bello edit
The slide is about rational use of drugs, what influences it, factors and reasons, strategies to improve them, and choosing an intervention (WHO priorities).
81-240-1 Chapter 06
The chapter discusses drugs and delinquency among youth. It finds that most drug use is experimental and involves alcohol, tobacco, and marijuana. The relationship between drug use and delinquency is complex, with evidence that drug use can both cause and result from delinquency. Effective interventions include life skills training to prevent drug use and treatment programs that combine legal action with individualized treatment plans, such as drug courts.
Introduction to rational use of drugs and role of pharmacist in rational use...
This document discusses strategies for promoting rational use of drugs in healthcare systems. It recommends establishing a national drug regulatory authority to oversee drug quality, developing treatment guidelines and an essential drug list. Healthcare professionals should be provided drug information and undergo continuing education on rational prescribing. Generic names should be used and drugs prescribed according to their intended therapeutic uses and appropriate dosages. Quality of drugs must be ensured and irrational self-medication discouraged through public education. Monitoring drug use through indicators can help evaluate prescribing practices and promote rational drug utilization.
Frances harding general_session
National Rx Drug Abuse Summit, April 2-4, 2013. General Session presentation, "Prevention and Prosecution," Frances M. Harding, Director, Center for Substance Abuse Prevention, SAMHSA
Seminar on Addiction and Substance use
This document provides an overview of addiction and substance use. It defines addiction as a chronic disease involving brain circuits, genetics, environment and life experiences. It discusses types of addiction including substance and behavioral addiction. Common addictions include tobacco, alcohol, drugs, gambling, food, video games and internet. The document reviews prevalence data on addiction from various sources. It also discusses treatment approaches for behavioral and substance use disorders including detox, individual therapy, group therapy and rehabilitation programs. Recent studies on substance use during the COVID-19 pandemic are also summarized.
WHRF - Human rights, drug policy and HIV by Anya Sarang
Présentation de Anya Sarang sur "Human rights, drug policy and HIV" lors du Forum Mondial des Droits de l'Homme, Novembre 2014.
Pour plus d'informations :
- Site web : http://fmdh-2014.org/fr/
- Facebook : https://www.facebook.com/FMDH2014
- Twitter : https://twitter.com/FMDH2014
- Youtube : https://www.youtube.com/user/FMDH2014
Similar to Cannabis Science & Policy Summit - Day 1 - Wetterau (20)
EVERFI Webinar: Addressing Prescription Drug Abuse on Campus
EVERFI Webinar: Addressing Prescription Drug Abuse on Campus
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Kyle molina harm reduction midterm project unm crp 275 community change in a ...
Rational Drug use - Group 5 presentation 2.0 bello edit
Rational Drug use - Group 5 presentation 2.0 bello edit
Introduction to rational use of drugs and role of pharmacist in rational use...
Introduction to rational use of drugs and role of pharmacist in rational use...
WHRF - Human rights, drug policy and HIV by Anya Sarang
WHRF - Human rights, drug policy and HIV by Anya Sarang
Recently uploaded
Equivariant neural networks and representation theory
Or: Beyond linear.
Abstract: Equivariant neural networks are neural networks that incorporate symmetries. The nonlinear activation functions in these networks result in interesting nonlinear equivariant maps between simple representations, and motivate the key player of this talk: piecewise linear representation theory.
Disclaimer: No one is perfect, so please mind that there might be mistakes and typos.
dtubbenhauer@gmail.com
Corrected slides: dtubbenhauer.com/talks.html
The debris of the ‘last major merger’ is dynamically young
The Milky Way’s (MW) inner stellar halo contains an [Fe/H]-rich component with highly eccentric orbits, often referred to as the
‘last major merger.’ Hypotheses for the origin of this component include Gaia-Sausage/Enceladus (GSE), where the progenitor
collided with the MW proto-disc 8–11 Gyr ago, and the Virgo Radial Merger (VRM), where the progenitor collided with the
MW disc within the last 3 Gyr. These two scenarios make different predictions about observable structure in local phase space,
because the morphology of debris depends on how long it has had to phase mix. The recently identified phase-space folds in Gaia
DR3 have positive caustic velocities, making them fundamentally different than the phase-mixed chevrons found in simulations
at late times. Roughly 20 per cent of the stars in the prograde local stellar halo are associated with the observed caustics. Based
on a simple phase-mixing model, the observed number of caustics are consistent with a merger that occurred 1–2 Gyr ago.
We also compare the observed phase-space distribution to FIRE-2 Latte simulations of GSE-like mergers, using a quantitative
measurement of phase mixing (2D causticality). The observed local phase-space distribution best matches the simulated data
1–2 Gyr after collision, and certainly not later than 3 Gyr. This is further evidence that the progenitor of the ‘last major merger’
did not collide with the MW proto-disc at early times, as is thought for the GSE, but instead collided with the MW disc within
the last few Gyr, consistent with the body of work surrounding the VRM.
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...University of Maribor
Slides from:
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Track: Artificial Intelligence
https://www.etran.rs/2024/en/home-english/Deep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless ReproducibilityUniversity of Rennes, INSA Rennes, Inria/IRISA, CNRS
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
Applied Science: Thermodynamics, Laws & Methodology.pdf
When I was asked to give a companion lecture in support of ‘The Philosophy of Science’ (https://shorturl.at/4pUXz) I decided not to walk through the detail of the many methodologies in order of use. Instead, I chose to employ a long standing, and ongoing, scientific development as an exemplar. And so, I chose the ever evolving story of Thermodynamics as a scientific investigation at its best.
Conducted over a period of >200 years, Thermodynamics R&D, and application, benefitted from the highest levels of professionalism, collaboration, and technical thoroughness. New layers of application, methodology, and practice were made possible by the progressive advance of technology. In turn, this has seen measurement and modelling accuracy continually improved at a micro and macro level.
Perhaps most importantly, Thermodynamics rapidly became a primary tool in the advance of applied science/engineering/technology, spanning micro-tech, to aerospace and cosmology. I can think of no better a story to illustrate the breadth of scientific methodologies and applications at their best.
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...Abdul Wali Khan University Mardan,kP,Pakistan
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skillsSharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero WaterTexas Alliance of Groundwater Districts
Presented at June 6-7 Texas Alliance of Groundwater Districts Business MeetingThornton ESPP slides UK WW Network 4_6_24.pdf
ESPP presentation to EU Waste Water Network, 4th June 2024 “EU policies driving nutrient removal and recycling
and the revised UWWTD (Urban Waste Water Treatment Directive)”
bordetella pertussis.................................ppt
Bordettela is a gram negative cocobacilli spread by air born drop let
Micronuclei test.M.sc.zoology.fisheries.
Current Ms word generated power point presentation covers major details about the micronuclei test. It's significance and assays to conduct it. It is used to detect the micronuclei formation inside the cells of nearly every multicellular organism. It's formation takes place during chromosomal sepration at metaphase.
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
Abnormal or anomalous secondary growth in plants. It defines secondary growth as an increase in plant girth due to vascular cambium or cork cambium. Anomalous secondary growth does not follow the normal pattern of a single vascular cambium producing xylem internally and phloem externally.
Bob Reedy - Nitrate in Texas Groundwater.pdf
Presented at June 6-7 Texas Alliance of Groundwater Districts Business Meeting
SAR of Medicinal Chemistry 1st by dk.pdf
In this presentation include the prototype drug SAR on thus or with their examples .
Syllabus of Second Year B. Pharmacy
2019 PATTERN.
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
Context. With a mass exceeding several 104 M⊙ and a rich and dense population of massive stars, supermassive young star clusters
represent the most massive star-forming environment that is dominated by the feedback from massive stars and gravitational interactions
among stars.
Aims. In this paper we present the Extended Westerlund 1 and 2 Open Clusters Survey (EWOCS) project, which aims to investigate
the influence of the starburst environment on the formation of stars and planets, and on the evolution of both low and high mass stars.
The primary targets of this project are Westerlund 1 and 2, the closest supermassive star clusters to the Sun.
Methods. The project is based primarily on recent observations conducted with the Chandra and JWST observatories. Specifically,
the Chandra survey of Westerlund 1 consists of 36 new ACIS-I observations, nearly co-pointed, for a total exposure time of 1 Msec.
Additionally, we included 8 archival Chandra/ACIS-S observations. This paper presents the resulting catalog of X-ray sources within
and around Westerlund 1. Sources were detected by combining various existing methods, and photon extraction and source validation
were carried out using the ACIS-Extract software.
Results. The EWOCS X-ray catalog comprises 5963 validated sources out of the 9420 initially provided to ACIS-Extract, reaching a
photon flux threshold of approximately 2 × 10−8 photons cm−2
s
−1
. The X-ray sources exhibit a highly concentrated spatial distribution,
with 1075 sources located within the central 1 arcmin. We have successfully detected X-ray emissions from 126 out of the 166 known
massive stars of the cluster, and we have collected over 71 000 photons from the magnetar CXO J164710.20-455217.
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
The pygmy halfbeak Dermogenys colletei, is known for its viviparous nature, this presents an intriguing case of relatively low fecundity, raising questions about potential compensatory reproductive strategies employed by this species. Our study delves into the examination of fecundity and the Gonadosomatic Index (GSI) in the Pygmy Halfbeak, D. colletei (Meisner, 2001), an intriguing viviparous fish indigenous to Sarawak, Borneo. We hypothesize that the Pygmy halfbeak, D. colletei, may exhibit unique reproductive adaptations to offset its low fecundity, thus enhancing its survival and fitness. To address this, we conducted a comprehensive study utilizing 28 mature female specimens of D. colletei, carefully measuring fecundity and GSI to shed light on the reproductive adaptations of this species. Our findings reveal that D. colletei indeed exhibits low fecundity, with a mean of 16.76 ± 2.01, and a mean GSI of 12.83 ± 1.27, providing crucial insights into the reproductive mechanisms at play in this species. These results underscore the existence of unique reproductive strategies in D. colletei, enabling its adaptation and persistence in Borneo's diverse aquatic ecosystems, and call for further ecological research to elucidate these mechanisms. This study lends to a better understanding of viviparous fish in Borneo and contributes to the broader field of aquatic ecology, enhancing our knowledge of species adaptations to unique ecological challenges.
Recently uploaded (20)
Equivariant neural networks and representation theory
Equivariant neural networks and representation theory
The debris of the ‘last major merger’ is dynamically young
The debris of the ‘last major merger’ is dynamically young
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...
Deep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless Reproducibility
Applied Science: Thermodynamics, Laws & Methodology.pdf
Applied Science: Thermodynamics, Laws & Methodology.pdf
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
bordetella pertussis.................................ppt
bordetella pertussis.................................ppt
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
Cannabis Science & Policy Summit - Day 1 - Wetterau
- 1. ASAM’s Marijuana Policy Norman Wetterau MD
- 2. New Papers in 2015 • ASAM Paper • American Academy of Pediatrics – Position Paper: – Technical paper: Reviews medical evidence, also an extensive review of decriminalization – Both organizations support decriminalization and treatment rather than legalization
- 3. 3 studies in Australia and New Zealand Silins, et al Lancet Psychiatry (Sept 2014) ref.11 • Marijuana use before age 18: none, less than monthly, monthly or more, weekly or more, daily • High school completion: 80% nonusers to 70% monthly, 53% in weekly or more users • Cannabis dependence: 4% nonusers to 19%(39/202) monthly and 48% (92/203) weekly or more • other drug use: 9% nonusers 21% less monthly, 35% weekly
- 4. 1. ASAM supports the decriminalization of marijuana, which would reduce penalties for marijuana possession for personal use to civil offenses linked to contingencies, such as mandated referral to clinical assessment, educational activities, and, when indicated, formal treatment for addiction or other substance- related disorders. 2. ASAM does not support the legalization of marijuana and recommends that jurisdictions that have not acted to legalize marijuana be most cautious and not adopt a policy of legalization until more can be learned from the natural experiments now underway in jurisdictions that have legalized marijuana.
- 5. What do we do? • Evaluation: possibly web-based, or in person(second offense),confidential • Look for usage, CRAFFT, other drug use, mental health issues and offer referral for help • Contingencies: fine, loss of drivers license. How about loss of confidentiality?
- 6. What about states where recreational marijuana is legal? • In states that choose otherwise: 8 recommen- dations: warning labels, sold only in state stores, not sold to anyone under age 25, etc. • Implement public awareness campaigns which highlight the risks of marijuana use to discourage vulnerable populations, including youth (i.e., adolescents and young adults), individuals with mental illness, and those with a history of addiction involving alcohol or other drugs, from using marijuana products.
- 7. Medical Marijuana • FDA approved, but in states that choose otherwise like New York ASAM recommends • In general, any product purported to be medicine should have the appearance of medicine, such as a pill, capsule or wafer, and should not appear as candy or food. • Plus other recommendations similar to New York’s Law
- 8. Clinical Recommendations 1. ASAM recommends that addiction medicine physicians and other clinicians educate their patients about the known medical risks of marijuana use, 2. ASAM recommends a significant expansion of opportunities for youth with cannabis use disorder to receive medically necessary treatment as well as for youth to receive appropriate clinical preventive services related to cannabis use, and that private and public insurance coverage be available for youth to be able to access such services. 4. ASAM supports the expanded establishment of clinical entities such as Student Assistance Programs in middle schools, high schools, and post-secondary schools, including professional schools,
- 9. One more Clinical Recommendations 3. ASAM supports the consensus of most addiction professionals that clinicians should counsel persons suffering from addiction about the need for abstinence from marijuana and synthetic cannabinoids and the role of cannabis and cannabinoid use in precipitating relapse, even if the original drug involved in their addiction is a substance other than marijuana